About this trial
Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring \>48 hours of age). In Canada, \~250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every year; of these \~35-40% die. Unlike for adult patients, there is little evidence to inform practice. While several medications are used by clinicians, the most frequently used medications are Dopamine (DA) and Norepinephrine (NE). However, their relative impact on patient outcomes and safety is not known resulting in significant uncertainty and inter- and intra-unit variability in practice. Conducting large randomized trials in this subpopulation can be operationally challenging and expensive. Comparative effectiveness research (CER), is a feasible alternative which can generate high-quality real-world evidence using real-world data, by comparing the impact of different clinical practices.
Aim: To conduct an international CER study, using a pragmatic clinical trial design, in conjunction with the existing infrastructure of the Canadian Neonatal Network to identify the optimal management of hypotension in very preterm neonates with suspected LOS.
Objective: To compare the relative effectiveness and safety of pharmacologically equivalent dosages of DA versus NE for primary pharmacotherapy for fluid-unresponsive hypotension in preterm infants born ≤ 32 weeks gestational age with suspected LOS.
Hypothesis: Primary treatment with NE will be associated with a lower mortality
Methods: This CER project will compare management approach at the unit-level allowing inclusion of all eligible patients admitted during the study period. 16 centers in Canada, 2 centers in Ireland, 1 center in each of Israel, Spain and the UK, and 6 centers in the United States have agreed to standardize their practice. All eligible patients deemed circulatory insufficient will receive fluid therapy (minimum 10-20 cc/kg). If hypotension remains unresolved:
Dopamine Units: start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response
Norepinephrine Units: start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
≤32 weeks gestational age and > 48 hours of life
Receiving primary vasopressor therapy with Dopamine or Norepinephrine in the context of suspected late-onset sepsis or necrotizing enterocolitis with systemic hypotension (defined as: culture positive or negative bloodstream infection)
Disqualifiers
Known chromosomal or genetic anomalies
Receiving primary therapy with agents other than Dopamine or Norepinephrine
Trial population
All preterm infants born ≤32 weeks gestational age and \> 48 hours of life with suspected sepsis with systemic hypotension admitted to the participating sites and meeting the above eligibility criteria will be included in the study.
Trial design
Cohort
Prospective
Treatments tested in this trial
Dopamine
DrugStart at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.
Norepinephrine
DrugStart at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
Treatment groups
Trial outcomes
Primary outcomes
All cause in-hospital mortality
Death before discharge
Secondary outcomes
Episode-related death
Episode-related death (yes or no- binary variable)
Treatment failure rate
Need for further dose escalation or use of additional agents (treatment failure = hypotension unresolved after reaching max dose (15mics/kg/min in Dopamine units and 0.15 mics/kg/min in Norepinephrine units)
New diagnosis of severe neurological injury
Grade III or Grade IV intraventricular hemorrhage or periventricular leukomalacia (yes or no- binary variable)
Bronchopulmonary dysplasia
Need for oxygen or positive pressure respiratory support at 36 weeks postmenstrual age (PMA) (yes or no- binary variable)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Mount Sinai Hospital, Canada
Lead sponsor
Sunnybrook Health Sciences Centre
Collaborator
The Hospital for Sick Children
Collaborator
London Health Sciences Centre
Collaborator
Windsor Regional Hospital
Collaborator
Foothills Medical Centre
Collaborator
Health Sciences Centre, Winnipeg, Manitoba
Collaborator
St. Boniface Hospital
Collaborator
Jewish General Hospital
Collaborator
St. Justine's Hospital
Collaborator
IWK Health Centre
Collaborator
University College Cork
Collaborator
Coombe Women and Infants University Hospital
Collaborator
Island Health, Victoria, BC
Collaborator
Assaf-Harofeh Medical Center
Collaborator
Dayton Children's Hospital
Collaborator
Banner University Medical Center
Collaborator
Methodist Healthcare - Memphis
Collaborator
Hospital Universitario La Paz
Collaborator
McMaster Children's Hospital
Collaborator
Children's Hospital of Eastern Ontario
Collaborator
BC Women's Hospital & Health Centre
Collaborator
Stony Brook University
Collaborator
Children's Hospital at Montefiore
Collaborator
Golisano Children's Hospital
Collaborator